Navigation Links
Osteotech Announces Fourth Quarter and Full Year Earnings Release and Conference Call Schedule
Date:2/15/2008

EATONTOWN, N.J., Feb. 15 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE) announced today that the Company's fourth quarter and year ended December 31, 2007 financial results will be released Wednesday, February 20, 2008. A conference call will be conducted by Sam Owusu-Akyaw, President and Chief Executive Officer, as well as other members of Osteotech management, on Wednesday, February 20, 2008, at 9:00 a.m. Eastern time. You are invited to listen to the conference call by dialing 1-706-643-1624. Automated playback will be available two hours after completion of the live call through midnight, Wednesday, March 5, 2008 by dialing 1-706-645-9291 and indicating access code 34462919.

A live, listen-only webcast of our conference call will also be available at our investor site at http://www.osteotech.com on the Financial Highlights page. A replay of the conference call and the question/answer session will be available at the Company's website for approximately 14 days following the call. It will be necessary to have RealPlayer installed on your computer.

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech, this press release or the conference call, please go to Osteotech's website at http://www.osteotech.com.


'/>"/>
SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Osteotech to Present at Sidoti Conference in San Francisco
2. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
3. Keryx Biopharmaceuticals Announces Additions to Management Team
4. Sigma-Aldrich Announces New Prestige Antibodies(TM) Line for Proteomics and Cell Biology Researchers
5. Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results
6. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
7. Telik Announces Year-End Financial Release, Conference Call and Webcast
8. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results Teleconference and Webcast
9. GeoPharma Announces Record Revenues in Third Quarter Results
10. Angiotech announces results for the fourth quarter ended December 31, 2007
11. Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... -- VMS BioMarketing, a leading provider of patient support solutions, has ... (CNE) network, which will launch this week. The VMS CNEs ... professionals to enhance the patient care experience by delivering peer-to-peer ... care professionals to help women who have been diagnosed and ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced ... to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B ... to cross the cell membrane and bind intracellular STAT3 and inhibit its function. ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... event entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, ... was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... of 13 prestigious awards honoring scientists who have made outstanding ... a scheduled symposium during Pittcon 2018, the world’s leading conference and exposition for ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by ... Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to ... USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):